Clinical Profile and Treatment Response to Conventional DMARDs in a Tertiary Care Hospital of Pakistan
Background Conventional disease modifying anti-rheumatic drugs (DMARDs) are the first line drugs in a conventional DMARDs in Pakistan. Methods and materials This prospective cohort study was conducted in rheumatology department of FFH Rawalpindi from October 2023 till March 2024. 224 cases of treatm...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
World Scientific Publishing
2024-01-01
|
| Series: | Journal of Clinical Rheumatology and Immunology |
| Online Access: | https://www.worldscientific.com/doi/10.1142/S2661341724740559 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background Conventional disease modifying anti-rheumatic drugs (DMARDs) are the first line drugs in a conventional DMARDs in Pakistan. Methods and materials This prospective cohort study was conducted in rheumatology department of FFH Rawalpindi from October 2023 till March 2024. 224 cases of treatment naïve early RA, diagnosed on the basis of ACR2010 criteria, were included. Patients were started on Methotrexate or other conventional. Baseline daa were collected for demographic, clinical parameters including age, gender, smoking, BMI, RA duration and serology. Disease activity was assessed by DAS28 CRP at 3 months for assessing the response to treatment. Correlations and comparisons were performed by Pearson’s correlation coefficient and independent sample t-test. Statistically significance p value was 0.05. Results Females constituted19six (87.5%) and males 22(12.5%) patients. 130 patients were seropositive, 94 were seronegative. 13 patients were smokers(..%). Radiographic damage was present in 67 patients. Mean DAS28 of the study population was 3.05± 89. RA duration was 11.07± 10.70 years. BMI was 27.70± 22.48kg/m2. Table I and II show the results of correlation and comparison of the clinical features with respect to disease activity score. Conclusion Patients with higher BMI has poorer response to conventional DMARDs. Weight optimization may be important step in improving the response to DMARDs in patients with RA. |
|---|---|
| ISSN: | 2661-3417 2661-3425 |